Concerning lung cancer, THZ1, a selective CDK7 covalent inhibitor, has recently been shown to be effective in reducing the expression of superenhancer-associated genes and inhibiting growth of small cell lung cancer (SCLC) (14). Here, CDK7 is linked to small cell lung carcinoma.